ResearcherIndiana University IndianapolisActive in the last 2 years
Trang K. Nguyen
Matched on ORCID iD 0000-0002-1207-351X; OpenAlex author ID A5073793965. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 6
- Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
- Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
- Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
- Patients with deleterious germline mutations: A heterogeneous population for pancreatic cancer screening? Co-author DOI 10.1002/jso.27289↗
- Neoadjuvant therapy at local versus outside institutions does not adversely impact surgical timing or long-term outcomes in patients with pancreatic adenocarci… Last author DOI 10.1016/j.surg.2022.06.046↗
- Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy. Co-author DOI 10.1007/s11605-020-04723-2↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Michael Garrett House · 3 shared papers, 2020–2023 · strength 0.47
- Paper Patients with deleterious germline mutations: A heterogeneous population for pancreatic cancer screening? DOI 10.1002/jso.27289↗
- Paper Neoadjuvant therapy at local versus outside institutions does not adversely impact surgical timing or long-term outcome… DOI 10.1016/j.surg.2022.06.046↗
- Paper Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After P… DOI 10.1007/s11605-020-04723-2↗
- Nicholas Joseph Zyromski · 3 shared papers, 2020–2023 · strength 0.47
- Paper Patients with deleterious germline mutations: A heterogeneous population for pancreatic cancer screening? DOI 10.1002/jso.27289↗
- Paper Neoadjuvant therapy at local versus outside institutions does not adversely impact surgical timing or long-term outcome… DOI 10.1016/j.surg.2022.06.046↗
- Paper Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After P… DOI 10.1007/s11605-020-04723-2↗
- Eugene P. Ceppa · 3 shared papers, 2020–2023 · strength 0.47
- Paper Patients with deleterious germline mutations: A heterogeneous population for pancreatic cancer screening? DOI 10.1002/jso.27289↗
- Paper Neoadjuvant therapy at local versus outside institutions does not adversely impact surgical timing or long-term outcome… DOI 10.1016/j.surg.2022.06.046↗
- Paper Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After P… DOI 10.1007/s11605-020-04723-2↗
- Alexandra M. Roch · 2 shared papers, 2023 · strength 0.37
- Rachel C. Kim · 2 shared papers, 2023 · strength 0.37
- Christian Max Schmidt · 2 shared papers, 2020–2023 · strength 0.28
- Paper Neoadjuvant therapy at local versus outside institutions does not adversely impact surgical timing or long-term outcome… DOI 10.1016/j.surg.2022.06.046↗
- Paper Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After P… DOI 10.1007/s11605-020-04723-2↗
- Christopher M. Schmidt · 1 shared paper, 2023 · strength 0.19
- Mark A. Tann · 1 shared paper, 2020 · strength 0.10
- Katelyn F. Flick · 1 shared paper, 2020 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.